Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290901 · ClinicalTrials.gov registry record · Phase 4
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 754
- Enrollment target
NCT00290901: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00290901 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 754 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290901, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 754 participants
- Enrollment target
Study Summary
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
Interventions
- DRUG Tramadol Hydrochloride 50mg
- DRUG Celebrex 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2006-03 |
| Phase | Phase 4 |
What the finished NCT00290901 record still lists
NCT00290901 is an interventional study that assigns participants to a tested intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 2 interventions - of which Tramadol Hydrochloride 50mg is the first listed.
NCT00290901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00290901 about?
NCT00290901 is a clinical study titled "Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.". This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
What is the current status of trial NCT00290901?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 754 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00290901?
The interventions under investigation include: Tramadol Hydrochloride 50mg (DRUG), Celebrex 200mg (DRUG).
Who is sponsoring clinical trial NCT00290901?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00290901's enrollment target sits among peer trials
754 106th of 2000 higher than 1,895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia